Last kr319.70 DKK
Change Today +3.70 / 1.17%
Volume 3.3M
NOVOB On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Mexico
Frankfurt
As of 11:06 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

novo nordisk a/s-b (NOVOB) Snapshot

Open
kr317.30
Previous Close
kr316.00
Day High
kr319.70
Day Low
kr314.60
52 Week High
02/27/15 - kr319.70
52 Week Low
04/14/14 - kr226.20
Market Cap
847.2B
Average Volume 10 Days
3.4M
EPS TTM
kr10.10
Shares Outstanding
2.1B
EX-Date
03/20/15
P/E TM
31.6x
Dividend
kr5.00
Dividend Yield
1.41%
Current Stock Chart for NOVO NORDISK A/S-B (NOVOB)

Related News

No related news articles were found.

novo nordisk a/s-b (NOVOB) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,957 Employees
Last Reported Date: 02/5/15
Founded in 1925

novo nordisk a/s-b (NOVOB) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo nordisk a/s-b (NOVOB) Key Developments

Novo Nordisk Announces Positive Phase 2 OG217SC Data for Oral Formulation of Semaglutide

Emisphere Technologies Inc. highlighted positive Phase 2 data from Eligen licensee Novo Nordisk pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.

Novo Nordisk Announces Positive Results for Phase 2 Trial with Oral Semaglutide in People with Type 2 Diabetes

Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks.

Novo Nordisk To List NNIT

Novo Nordisk A/S (CPSE:NOVO B) is planning to list NNIT A/S on Copenhagen's stock exchange within four to five weeks. "If everything goes well we will have NNIT listed on the Copenhagen stock exchange in four to five weeks," Jesper Brandgaard, Chief Financial Officer at Novo Nordisk and Chairman of NNIT told Reuters.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVOB:DC kr319.70 DKK +3.70

NOVOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.50 USD -0.02
Amgen Inc $157.72 USD -1.25
Biogen Idec Inc $409.59 USD -0.51
Bristol-Myers Squibb Co $60.92 USD -0.54
Reckitt Benckiser Group PLC 5,860 GBp +70.00
View Industry Companies
 

Industry Analysis

NOVOB

Industry Average

Valuation NOVOB Industry Range
Price/Earnings 29.3x
Price/Sales 8.6x
Price/Book 19.0x
Price/Cash Flow 23.5x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO NORDISK A/S-B, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.